This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.
Patients who voluntarily participate in this study, completely understand this study, and voluntarily sign the informed consent form (ICF).
ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1.
Life expectancy ≥ 3 months.
Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies.
Inflammatory breast cancer.
Patients unsuitable for endocrine therapy at the investigator's discretion.
History of other malignancies prior to the start of study treatment.
Patients with known metastases to central nervous system.